RIFERIMENTI BIBLIOGRAFICI
1. Akari, H., T. Fukumori, and A. Adachi. 2000. Cell-dependent requirement of human immunodeficiency virus type 1 gp41 cytoplasmic tail for Env incorporation into virions. J Virol 74:4891-3.
2. Akari, H., A. Yoshida, T. Fukumori, and A. Adachi. 2000. Host cell-dependent replication of HIV-1 mutants with deletions in gp41 cytoplasmic tail region is independent of the function of Vif. Microbes Infect 2:1019-23.
3. Ali, A., H. L. Ng, M. D. Dagarag, and O. O. Yang. 2005. Evasion of cytotoxic T lymphocytes is a functional constraint maintaining HIV-1 Nef expression. Eur J Immunol 35:3221-8.
4. Bendinelli, M., M. Pistello, S. Lombardi, A. Poli, C. Garzelli, D. Matteucci, L. Ceccherini-Nelli, G. Malvaldi, and F. Tozzini. 1995. Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev 8:87-112.
5. Berlioz-Torrent, C., B. L. Shacklett, L. Erdtmann, L. Delamarre, I. Bouchaert, P. Sonigo, M. C. Dokhelar, and R. Benarous. 1999. Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. J Virol 73:1350-61.
6. Bigornia, L., K. M. Lockridge, and E. E. Sparger. 2001. Construction and in vitro characterization of attenuated feline immunodeficiency virus long terminal repeat mutant viruses. J Virol 75:1054-60.
7. Boge, M., S. Wyss, J. S. Bonifacino, and M. Thali. 1998. A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor. J Biol Chem 273:15773-8.
8. Bogers, W. M., C. Cheng-Mayer, and R. C. Montelaro. 2000. Developments in preclinical AIDS vaccine efficacy models. Aids 14 Suppl 3: S141-51.
9. Bowers, K., A. Pelchen-Matthews, S. Honing, P. J. Vance, L. Creary, B. S. Haggarty, J. Romano, W. Ballensiefen, J. A. Hoxie, and M. Marsh. 2000. The simian immunodeficiency virus envelope glycoprotein
contains multiple signals that regulate its cell surface expression and endocytosis. Traffic 1:661-74.
10. Bultmann, A., W. Muranyi, B. Seed, and J. Haas. 2001. Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibits cell surface expression. J Virol 75:5263-76.
11. Burkhard, M. J., and G. A. Dean. 2003. Transmission and immunopathogenesis of FIV in cats as a model for HIV. Curr HIV Res 1:15-29.
12. de Parseval, A., and J. H. Elder. 1999. Demonstration that orf2 encodes the feline immunodeficiency virus transactivating (Tat) protein and characterization of a unique gene product with partial rev activity. J Virol 73:608-17.
13. de Parseval, A., S. V. Su, J. H. Elder, and B. Lee. 2004. Specific interaction of feline immunodeficiency virus surface glycoprotein with human DC-SIGN. J Virol 78:2597-600.
14. Deschambeault, J., J. P. Lalonde, G. Cervantes-Acosta, R. Lodge, E. A. Cohen, and G. Lemay. 1999. Polarized human immunodeficiency virus budding in lymphocytes involves a tyrosine-based signal and favors cell-to-cell viral transmission. J Virol 73:5010-7.
15. Flynn, J. N., C. A. Cannon, J. C. Neil, and O. Jarrett. 1997. Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection. J Virol 71:7586-92.
16. Flynn, J. N., P. Keating, M. J. Hosie, M. Mackett, E. B. Stephens, J. A. Beatty, J. C. Neil, and O. Jarrett. 1996. Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination. J Immunol 157:3658-65.
17. Fultz, P. N., P. J. Vance, M. J. Endres, B. Tao, J. D. Dvorin, I. C. Davis, J. D. Lifson, D. C. Montefiori, M. Marsh, M. H. Malim, and J. A. Hoxie. 2001. In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. J Virol 75:278-91.
18. Garg, H., F. J. Fuller, and W. A. Tompkins. 2004. Mechanism of feline immunodeficiency virus envelope glycoprotein-mediated fusion. Virology 321:274-86.
19. Gemeniano, M. C., E. T. Sawai, C. M. Leutenegger, and E. E. Sparger. 2003. Feline immunodeficiency virus ORF-A is required for virus particle formation and virus infectivity. J Virol 77:8819-30.
20. Gemeniano, M. C., E. T. Sawai, and E. E. Sparger. 2004. Feline immunodeficiency virus Orf-A localizes to the nucleus and induces cell cycle arrest. Virology 325:167-74.
21. Hosie, M. J., T. Dunsford, D. Klein, B. J. Willett, C. Cannon, R. Osborne, J. Macdonald, N. Spibey, N. Mackay, O. Jarrett, and J. C. Neil. 2000. Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus. J Virol 74:9403-11.
22. Hosie, M. J., and J. N. Flynn. 1996. Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection. J Virol 70:7561-8.
23. Hosie, M. J., D. Klein, J. M. Binley, T. H. Dunsford, O. Jarrett, J. C. Neil, E. Knapp, S. Giannecchini, D. Matteucci, M. Bendinelli, J. A. Hoxie, and B. J. Willett. 2005. Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env. J Virol 79:1954-7.
24. Karlas, J. A., K. H. Siebelink, M. A. Peer, W. Huisman, A. M. Cuisinier, G. F. Rimmelzwaan, and A. D. Osterhaus. 1999. Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection. J Gen Virol 80 (Pt 3):761-5.
25. Lerner, D. L., and J. H. Elder. 2000. Expanded host cell tropism and cytopathic properties of feline immunodeficiency virus strain PPR subsequent to passage through interleukin-2-independent T cells. J Virol 74:1854-63.
26. Letvin, N. L., Y. Huang, B. K. Chakrabarti, L. Xu, M. S. Seaman, K. Beaudry, B. Korioth-Schmitz, F. Yu, D. Rohne, K. L. Martin, A. Miura, W. P. Kong, Z. Y. Yang, R. S. Gelman, O. G. Golubeva, D. C. Montefiori, J. R. Mascola, and G. J. Nabel. 2004. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 78:7490-7.
27. Lockridge, K. M., S. Himathongkham, E. T. Sawai, M. Chienand, and E. E. Sparger. 1999. The feline immunodeficiency virus vif gene is required for productive infection of feline peripheral blood mononuclear cells and monocyte-derived macrophages. Virology 261:25-30.
28. Maki, N., T. Miyazawa, M. Fukasawa, A. Hasegawa, M. Hayami, K. Miki, and T. Mikami. 1992. Molecular characterization and heterogeneity of feline immunodeficiency virus isolates. Arch Virol 123:29-45.
29. Matteucci, D., M. Pistello, P. Mazzetti, S. Giannecchini, D. Del Mauro, I. Lonetti, L. Zaccaro, C. Pollera, S. Specter, and M. Bendinelli. 1997. Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted. J Virol 71:8368-76.
30. Matteucci, D., A. Poli, P. Mazzetti, S. Sozzi, F. Bonci, P. Isola, L. Zaccaro, S. Giannecchini, M. Calandrella, M. Pistello, S. Specter, and M. Bendinelli. 2000. Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. J Virol 74:10911-9.
31. Norway, R. M., P. C. Crawford, C. M. Johnson, and A. Mergia. 2001. Thymic lesions in cats infected with a pathogenic molecular clone or an ORF-A/2-deficient molecular clone of feline immunodeficiency virus. J Virol 75:5833-41.
32. Osterhaus, A. D., E. Tijhaar, R. C. Huisman, W. Huisman, I. H. Darby, M. J. Francis, G. F. Rimmelzwaan, and K. H. Siebelink. 1996. Accelerated viremia in cats vaccinated with recombinant vaccinia virus expressing envelope glycoprotein of feline immunodeficiency virus. AIDS Res Hum Retroviruses 12:437-41.
33. Parren, P. W., J. P. Moore, D. R. Burton, and Q. J. Sattentau. 1999. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. Aids 13 Suppl A: S137-62.
34. Phillips, T. R., C. Lamont, D. A. Konings, B. L. Shacklett, C. A. Hamson, P. A. Luciw, and J. H. Elder. 1992. Identification of the Rev transactivation and Rev-responsive elements of feline immunodeficiency virus. J Virol 66:5464-71.
35. Pistello, M., F. Bonci, P. Isola, P. Mazzetti, A. Merico, L. Zaccaro, D. Matteucci, and M. Bendinelli. 2005. Evaluation of feline immunodeficiency virus ORF-A mutants as candidate attenuated vaccine. Virology 332:676-90.
36. Pistello, M., M. Moscardini, P. Mazzetti, F. Bonci, L. Zaccaro, P. Isola, G. Freer, S. Specter, D. Matteucci, and M. Bendinelli. 2002. Development of feline immunodeficiency virus ORF-A (tat) mutants: in vitro and in vivo characterization. Virology 298:84-95.
37. Rinaldo, C. R., Jr., L. A. Beltz, X. L. Huang, P. Gupta, Z. Fan, and D. J. Torpey, 3rd. 1995. Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men. AIDS Res Hum Retroviruses 11:481-9. 38. Sauter, M. M., A. Pelchen-Matthews, R. Bron, M. Marsh, C. C. LaBranche, P. J. Vance, J. Romano, B. S. Haggarty, T. K. Hart, W. M. Lee, and J. A. Hoxie. 1996. An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface. J Cell Biol 132:795-811.
39. Sharma, V. A., E. Kan, Y. Sun, Y. Lian, J. Cisto, V. Frasca, S. Hilt, L. Stamatatos, J. J. Donnelly, J. B. Ulmer, S. W. Barnett, and I. K. Srivastava. 2006. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines. Virology (in stampa).
40. Shimojima, M., T. Miyazawa, Y. Ikeda, E. L. McMonagle, H. Haining, H. Akashi, Y. Takeuchi, M. J. Hosie, and B. J. Willett. 2004. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 303:1192-5.
41. Talbott, R. L., E. E. Sparger, K. M. Lovelace, W. M. Fitch, N. C. Pedersen, P. A. Luciw, and J. H. Elder. 1989. Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci U S A 86:5743-7.
42. Thompson, F. J., J. Elder, and J. C. Neil. 1994. Cis- and trans-regulation of feline immunodeficiency virus: identification of functional binding sites in the long terminal repeat. J Gen Virol 75 (Pt 3):545-54. 43. Tomonaga, K., and T. Mikami. 1996. Molecular biology of the feline immunodeficiency virus auxiliary genes. J Gen Virol 77 (Pt 8):1611-21.
44. Vahlenkamp, T. W., E. J. Verschoor, N. N. Schuurman, A. L. van Vliet, M. C. Horzinek, H. F. Egberink, and A. de Ronde. 1997. A single amino acid substitution in the transmembrane envelope glycoprotein of feline immunodeficiency virus alters cellular tropism. J Virol 71:7132-5. 45. Wyss, S., C. Berlioz-Torrent, M. Boge, G. Blot, S. Honing, R. Benarous, and M. Thali. 2001. The highly conserved C-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type 1 envelope glycoprotein is critical for its association with the AP-1 clathrin adaptor [correction of adapter]. J Virol 75:2982-92.
46. Ye, L., Z. Bu, A. Vzorov, D. Taylor, R. W. Compans, and C. Yang. 2004. Surface stability and immunogenicity of the human immunodeficiency virus envelope glycoprotein: role of the cytoplasmic domain. J Virol 78:13409-19.
47. Yuste, E., J. D. Reeves, R. W. Doms, and R. C. Desrosiers. 2004. Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol 78:6775-85.
48. Zinkernagel, R. M. 2000. On immunological memory. Philos Trans R Soc Lond B Biol Sci 355:369-71.
